טוען...
Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice
Topical calcineurin inhibitors (TCIs), commercially available since 2000–2001, are the first and only topical medications approved for chronic treatment of atopic dermatitis (AD) in pediatric patients and remain a welcomed alternative to topical corticosteroids. In January 2006, the US Food and Drug...
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer International Publishing AG
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3669499/ https://ncbi.nlm.nih.gov/pubmed/23703374 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40257-013-0020-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|